UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (date of earliest event reported): May 6, 2011
Commission File No. 001-12575
|
UTAH MEDICAL PRODUCTS, INC.
|
|
|
(Exact name of Registrant as specified in its charter)
|
|
|
UTAH
|
87-0342734
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|
7043 South 300 West
|
|
|
Midvale, Utah 84047
|
|
|
Address of principal executive offices
|
|
Registrant's telephone number: (801) 566-1200
ITEM 5.07. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
On May 6, 2011 at the annual meeting, shareholders of the Company approved or indicated their preference on the following matters submitted to them for consideration:
|
Elected Ernst G. Hoyer as a director of the Company:
|
|||
|
For 2,644,531
|
Withheld 90,998
|
Broker Non-Votes 544,656
|
|
|
Elected James H. Beeson as a director of the Company:
|
|||
|
For 2,652,244
|
Withheld 83,285
|
Broker Non-Votes 544,656
|
|
|
Ratified the selection of Jones, Simkins P.C. as the Company’s independent public accounting firm for the year ended December 31, 2011:
|
|||
|
For 3,244,036
|
Against 14,717
|
Abstentions 21,432
|
|
|
Approved, on an advisory basis, the compensation paid to UTMD’s named executive officers, including the Compensation Discussion and Analysis, compensation tables and narrative discussion:
|
|||
|
For 2,697,042
|
Against 25,619
|
Abstentions 12,868
|
|
|
Indicated, on an advisory basis, their preference for annual shareholder votes on executive compensation:
|
|||
|
1 Year 2,367,054
|
2 Year 44,313
|
3 Year 293,886
|
Abstentions 30,277
|
SIGNATURES
Pursuant to the requirements of the Securities Exchanges Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
UTAH MEDICAL PRODUCTS, INC.
|
|
|
REGISTRANT
|
|
|
Date: 5/10/2011
|
By: /s/ Kevin L. Cornwell
|
|
Kevin L. Cornwell
|
|
|
CEO
|